Insulin Resistance Is Central to Long-Term Reversal of Histologic Nonalcoholic Steatohepatitis After Metabolic Surgery
Open accessThe DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.
Abstract
Context: Nonalcoholic steatohepatitis (NASH) is considered the hepatic counterpart of metabolic syndrome. Objective: This work aimed to investigate the determinants of NASH reversal in patients undergoing biliopancreatic diversion (BPD) in a 5-year follow-up study. Methods: This prospective study was conducted at Policlinico Universitario Agostino Gemelli. A total of 37 patients underwent fine-needle liver biopsy during BPD. Ultrasonography-guided percutaneous liver biopsy was obtained 5 years after the operation. The primary outcome of our study was histologic NASH reversal at 5-year follow-up. To better characterize the clinical variables involved in the resolution of NASH, we also compared patients without histologic NASH resolution at 5 years with those in whom NASH had disappeared. Results: At follow-up, NASH had reversed in 56.5% of the patients. The NAFLD activity score (NAS) improved from 3.7 ± 0.93 to 2 ± 1.11 (P < .001). Fibrosis reversed in 16% patients (P = .022), and 32% improved (95% CI, 0.05-0.54). No significant differences in body mass index or clinical parameters changes explained the effect of surgery on NASH, apart from the measure of insulin sensitivity post surgery. The Homeostasis Model Assessment of Insulin Resistance decreased from 3.31 ± 1.72 at baseline to 1.73 ± 1.08 (P < .001) after BPD, and the Matsuda index improved from 2.66 ± 1.79 to 4.73 ± 3.05 (P < .001). The lipid profile normalized (total cholesterol from 4.75 ± 1.18 to 3.32 ± 0.77 mmol/L, P < .001; low-density lipoprotein cholesterol from 2.92 ± 0.91 to 1.60 ± 0.51 mmol/L, P = .0001; high-density lipoprotein cholesterol from 0.97 ± 0.33 to 1.10 ± 0.35 mmol/L, P = .023; triglycerides from 2.52 ± 1.6 to 1.47 ± 0.67 mmol/L, P = .003). Neural network analysis showed that the end-study Matsuda index discriminated between responders and nonresponders with high accuracy (receiver operating characteristic area under the curve = 0.98%). Conclusion: Remission of NASH is driven by reversal of whole-body insulin resistance post intervention.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Pioglitazone therapy, GLP-1 RA therapy, and metabolic surgery have all been shown to reduce NASH activity; pioglitazone therapy and metabolic surgery may also improve hepatic fi brosis (188,292 -298).”
In the citing paper
“Russo et al. demonstrated fibrosis reversal in 16% of patients (p = 0.022) and improvement in 32% [51].”
From Impact of Bariatric Surgery and Endoscopic Therapies on Liver Health in Metabolic Dysfunction-Associated Steatotic Liver Disease: A Review (2025) · cites this paper as [51]
In the citing paper
“attributing this improvement primarily to reduced insulin resistance rather than weight loss alone [51].”
From Impact of Bariatric Surgery and Endoscopic Therapies on Liver Health in Metabolic Dysfunction-Associated Steatotic Liver Disease: A Review (2025) · cites this paper as [51]
In the citing paper
“one five-year follow-up study on 37 patients with biopsy-confirmed NASH who underwent BPD-DS found that 26 (70%) achieved NASH resolution”
From Impact of Bariatric Surgery and Endoscopic Therapies on Liver Health in Metabolic Dysfunction-Associated Steatotic Liver Disease: A Review (2025) · cites this paper as [51]
In the citing paper
“and it achieves high rates of type 2 diabetes remission, addressing a key driver of NAFLD [51,54].”
From Impact of Bariatric Surgery and Endoscopic Therapies on Liver Health in Metabolic Dysfunction-Associated Steatotic Liver Disease: A Review (2025) · cites this paper as [51]
3 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Matthews, D. R., Hosker, J. P., Rudenski, A. S., Naylor, B. A., Treacher, D. F., & Turner, R. C. (1985) · Diabetologia · doi:10.1007/bf00280883 · Cited by 31,502
Design and validation of a histological scoring system for nonalcoholic fatty liver disease†
Kleiner, D. E., Brunt, E. M., Van Natta, M., Behling, C., Contos, M. J., Cummings, O. W., Ferrell, L. D., Liu, Y., Torbenson, M. S., Unalp‐Arida, A., et al. (2005) · Hepatology · doi:10.1002/hep.20701 · Cited by 10,791
Younossi, Z. M., Koenig, A. B., Abdelatif, D., Fazel, Y., Henry, L., & Wymer, M. (2016) · Hepatology · doi:10.1002/hep.28431 · Cited by 10,781
Chalasani, N., Younossi, Z., Lavine, J. E., Charlton, M., Cusi, K., Rinella, M., Harrison, S. A., Brunt, E. M., & Sanyal, A. J. (2018) · Hepatology · doi:10.1002/hep.29367 · Cited by 7,239
Matsuda, M., & DeFronzo, R. A. (1999) · Diabetes Care · doi:10.2337/diacare.22.9.1462 · Cited by 5,621
EASL–EASD–EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease
(2016) · Journal of Hepatology · doi:10.1016/j.jhep.2015.11.004 · Cited by 4,836
Nonalcoholic Steatohepatitis: A Proposal for Grading and Staging The Histological Lesions
Brunt, E. M., Janney, C. G., Di Bisceglie, A. M., Neuschwander-Tetri, B. A., & Bacon, B. R. (1999) · American Journal of Gastroenterology · doi:10.1111/j.1572-0241.1999.01377.x · Cited by 3,907
Pioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis
Sanyal, A. J., Chalasani, N., Kowdley, K. V., McCullough, A., Diehl, A. M., Bass, N. M., Neuschwander-Tetri, B. A., Lavine, J. E., Tonascia, J., Unalp, A., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0907929 · Cited by 3,327
Mechanisms of Insulin Action and Insulin Resistance
Petersen, M. C., & Shulman, G. I. (2018) · Physiological Reviews · doi:10.1152/physrev.00063.2017 · Cited by 3,028
Nonalcoholic Fatty Liver Disease
Marchesini, G., Brizi, M., Bianchi, G., Tomassetti, S., Bugianesi, E., Lenzi, M., McCullough, A. J., Natale, S., Forlani, G., & Melchionda, N. (2001) · Diabetes · doi:10.2337/diabetes.50.8.1844 · Cited by 2,581
Research works printed but not linked: 1
- IBM Corp, 2017, IBM SPSS Statistics for Windows, Version 26.0
Cited by
Davies, M. J., Aroda, V. R., Collins, B. S., Gabbay, R. A., Green, J., Maruthur, N. M., Rosas, S. E., Del Prato, S., Mathieu, C., Mingrone, G., et al. (2022) · Diabetes Care · doi:10.2337/dci22-0034 · Cited by 2,104
Self-citationDavies, M. J., Aroda, V. R., Collins, B. S., Gabbay, R. A., Green, J., Maruthur, N. M., Rosas, S. E., Del Prato, S., Mathieu, C., Mingrone, G., et al. (2022) · Diabetologia · doi:10.1007/s00125-022-05787-2 · Cited by 1,048
Self-citationGutiérrez-Cuevas, J., Santos, A., & Armendariz-Borunda, J. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222111629 · Cited by 216
Hwang, J., Hwang, H., Shin, H., Kim, B. H., Kang, S. H., Yoo, J., Choi, M. Y., Lee, D. E., Jun, D. W., & Cho, Y. (2024) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2023.0384 · Cited by 66
Angelini, G., Castagneto‐Gissey, L., Salinari, S., BERTUZZI, A., Anello, D., Pradhan, M., Zschätzsch, M., Ritter, P., le Roux, C. W., Rubino, F., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-35310-5 · Cited by 41
Self-citationImpacts of bariatric surgery on adverse liver outcomes: a systematic review and meta-analysis
Wang, G., Huang, Y., Yang, H., Lin, H., Zhou, S., & Qian, J. (2023) · Surgery for Obesity and Related Diseases · doi:10.1016/j.soard.2022.12.025 · Cited by 29
Current strategies for nonalcoholic fatty liver disease treatment (Review)
Sun, J., Jin, X., & Li, Y. (2024) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2024.5412 · Cited by 29
Lembo, E., Russo, M. F., Verrastro, O., Anello, D., Angelini, G., Iaconelli, A., Guidone, C., Stefanizzi, G., Ciccoritti, L., Greco, F., et al. (2022) · Diabetes & Metabolism · doi:10.1016/j.diabet.2022.101363 · Cited by 25
Self-citationTasabehji, D., Saleh, S., & Mokadem, M. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14124012 · Cited by 14
Sinn, D. H., Kang, D., Güallar, E., Choi, S. C., Hong, Y. S., Park, Y., Cho, J., & Gwak, G. (2023) · PLoS ONE · doi:10.1371/journal.pone.0288820 · Cited by 13
van Rijswijk, A.-S., van Olst, N., Meijnikman, A. S., Acherman, Y. I. Z., Bruin, S., van de Laar, A. W. J. M., van Olden, C. C., Aydin, Ö., Börger, H., Beuers, U. H., et al. (2022) · Trials · doi:10.1186/s13063-022-06762-3 · Cited by 11
Guía de práctica clínica multidisciplinar de manejo de la esteatosis hepática metabólica
Romero‐Gómez, M., Escalada, J., Noguerol, M., Pérez, A., Carretero, J., Crespo, J., Mascort, J. J., Aguilar, I., Tinahones, F. J., Cañones, P., et al. (2025) · Gastroenterología y Hepatología · doi:10.1016/j.gastrohep.2025.502442 · Cited by 9
Gries, J. J., Chen, B., Bansal, M. B., Rodríguez, M., Alqahtani, S. A., Brennan, P., Lang, C. C., Tang, W. H. W., Lazarus, J. V., & Krittanawong, C. (2025) · Communications Medicine · doi:10.1038/s43856-025-00951-2 · Cited by 8
Can liquid biopsies for MASH help increase the penetration of metabolic surgery? A narrative review
Castagneto‐Gissey, L., Bornstein, S. R., & Mingrone, G. (2023) · Metabolism · doi:10.1016/j.metabol.2023.155721 · Cited by 8
Self-citationCheng, X., Fu, Z., Xie, W., Zhu, L., & Meng, J. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.1072513 · Cited by 7
Multidisciplinary clinical practice guideline on the management of metabolic hepatic steatosis
Romero‐Gómez, M., Escalada, J., Noguerol, M., Pérez, A., Carretero, J., Crespo, J., Mascort, J. J., Aguilar, I., Tinahones, F. J., Cañones, P., et al. (2025) · Gastroenterología y Hepatología (English Edition) · doi:10.1016/j.gastre.2025.502442 · Cited by 6
Angelini, G., Russo, S. L. M. L., & Mingrone, G. (2024) · Cell Stress and Chaperones · doi:10.1016/j.cstres.2024.02.003 · Cited by 5
Self-citationShah, A., Mohammadi, A., Haq, A., Walji, D., & Zevin, B. (2025) · Obesity Surgery · doi:10.1007/s11695-025-08246-0 · Cited by 4
Yilmaz, Y., Adalı, G., Ergenç, İ., Kaya, E., Gökçe, D. T., Keklikkıran, Ç., Zeybel, M., Us, G. D., Değertekın, B., Idılman, R., et al. (2026) · Hepatology forum/Hepatology forum (Online) · doi:10.14744/hf.2026.44190 · Cited by 5
Diabetes and Non‐alcoholic Fatty Liver Disease
Mantovani, A., Targher, G., & Byrne, C. D. (2024) · Wiley eBooks · doi:10.1002/9781119697473.ch57 · Cited by 1
Reichert, M., Strowitzki, M. J., Tuffs, C., Amati, A., Amin, D., Raj, S., Sprenger, T., Hecker, A., & Schneider, M. (2026) · Zeitschrift für Gastroenterologie · doi:10.1055/a-2927-4771 · Cited by 1
Romero-Gómez, M., Escalada, J., Noguerol, M., Pérez, A., Carretero, J., Crespo, J., Mascort, J. J., Aguilar, I., Tinahones, F., Cañones, P., et al. (2026) · Gastroenterología y Hepatología · doi:10.1016/j.gastrohep.2025.502639 · Cited by 1
Chmyr, N. V., Dutka, R. Y., Abrahamovych, K., Fedechko, Y. M., & Kurban, M. (2022) · INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine) · doi:10.22141/2224-0721.18.7.2022.1211 · Cited by 1
Non-alcoholic fatty liver disease: a current challenge of interdisciplinary research
Biryukova, E. V. (2024) · Meditsinskiy sovet = Medical Council · doi:10.21518/ms2024-159 · Cited by 1
Liu, J., Wang, Y., Zhou, X., Wen, Z., Chen, Y., Sun, Y., Su, S. S., Lin, W., Shen, R., Sun, X., et al. (2025) · Frontiers in Medicine · doi:10.3389/fmed.2025.1623808
Pan, Y., Qu, Y., Ma, H., Wang, M., Zhong, M., & Hu, S. (2026) · Frontiers in Medicine · doi:10.3389/fmed.2026.1780788
Romero-Gómez, M., Escalada, J., Noguerol, M., Pérez, A., Carretero, J., Crespo, J., Mascort, J. J., Aguilar, I., Tinahones, F., Cañones, P., et al. (2026) · Gastroenterología y Hepatología (English Edition) · doi:10.1016/j.gastre.2026.502639
Branovitskaya, N. S. (2024) · Health and Ecology Issues · doi:10.51523/2708-6011.2024-21-3-06
Metadata
- Authors
- Russo, M. F., Lembo, E., Mari, A., Angelini, G., Verrastro, O., Nanni, G., Pompili, M., Raffaelli, M., Vecchio, F. M., Bornstein, S. R., & Mingrone, G.
- Affiliations
- Università Cattolica del Sacro Cuore (IT)
- National Research Council (IT)
- King's College London (GB)
- Corresponding author
- Mingrone, Geltrude
- ORCID
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2020-11-28
- Volume
- 106
- Issue
- 3
- Pages
- 750-761
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W3106581502
- Cited by
- 28
- References
- 42
- Citations by year
- 2026: 4 · 2025: 6 · 2024: 7 · 2023: 2 · 2022: 8 · 2021: 1
- FWCI
- 1.97
- Type
- journal article
- Language
- en
- Open access
- green
- doi.org
- Licence
- academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model (vor)
- Locations
- The Journal of Clinical Endocrinology & Metabolism (publishedVersion)
- PubMed (publishedVersion)
- Zurich Open Repository and Archive (University of Zurich) (acceptedVersion)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion)
- Research Portal (King's College London) (submittedVersion)
- Zurich Open Repository and Archive (University of Zurich) (submittedVersion)
- Zurich Open Repository and Archive (University of Zurich)
- Topics
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Health Sciences › Medicine › Surgery › Bariatric Surgery and Outcomes
- Health Sciences › Medicine › Surgery › Organ Transplantation Techniques and Outcomes
- Keywords
- nonalcoholic steatohepatitis, biliopancreatic diversion, metabolic surgery, insulin resistance, insulin sensitivity, NAFLD activity score, liver fibrosis, Matsuda index, HOMA-IR, lipid profile, hepatic steatosis, metabolic syndrome, liver biopsy histology, long-term follow-up, type 2 diabetes
- MeSH terms
- Adult, Aged, Female, Follow-Up Studies, Humans, Insulin Resistance, Italy, Liver, Male, Middle Aged, Obesity, Morbid, Remission Induction, Cohort Studies, Biliopancreatic Diversion, Treatment Outcome, Biopsy, Fine-Needle, Bariatric Surgery, Young Adult, Non-alcoholic Fatty Liver Disease
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.